Dendreon Q1 Loss Narrows - Quick Facts

(RTTNews) - Dendreon Corp. (DNDN), a biotechnology firm focused on cancer treatments, Thursday reported first-quarter net loss of $36.38 million or $0.24 per share, narrower than $72.01 million or $0.48 per share in the prior year.

On a non-GAAP basis, net loss per share was $0.15, while the firm posted $0.36 per share last year.

On average, 16 analysts polled by Thomson Reuters expected the company to report a loss of $0.28 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue increased to $68.78 million from $67.59 million a year earlier. Analysts estimated revenues of $69.19 million for the quarter.